

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Erenumab (Aimovig)

Notes:

- Quantity Limits: Yes
- ^ Adequate trial is defined as 2 months treatment duration
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria: Non-formulary **erenumab (Aimovig)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient is between the ages of 18 and 75 years old
- Prescribed for treatment of chronic migraine or episodic migraine
- Patient has failed an adequate trial[^] of or patient has an allergy or intolerance* to fremanezumab (Ajovy) and galcanezumab (Emgality)
- Patient has failed an adequate trial[^] of or patient has an allergy or intolerance* to 3 additional preventative agents for migraine, 2 of which must include: tricyclic antidepressant (amitriptyline or nortriptyline), or beta-blocker (metoprolol or propranolol), or topiramate, or valproate, or onabotulinumtoxinA (Botox)
- Patient does not history of the following events in the past 12 months:
 - Myocardial infarction (MI), stroke, transient ischemic attack (TIA), coronary artery bypass surgery
- Patient is not currently pregnant or breastfeeding

Criteria for *new members* entering Kaiser Permanente already taking the medication who have not been reviewed previously, criteria for *current Kaiser Permanente members* already taking the medication who have not been reviewed previously, and continued use criteria for patients previously approved per the above criteria who are currently stable on the medication: Non-formulary **erenumab (Aimovig)** will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed for the treatment of migraine (episodic or chronic)
- Patient has failed an adequate trial[^] of or patient has an allergy or intolerance* to fremanezumab (Ajovy) and galcanezumab (Emgality)
- Patient does not have history of the following events in the past 12 months:
 - History of myocardial infarction (MI), stroke, transient ischemic attack (TIA), coronary artery bypass surgery

kp.org

Revised: 09/14/23
Effective: 11/02/23

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Erenumab (Aimovig)

- Patient is not currently pregnant or breastfeeding

kp.org

Revised: 09/14/23
Effective: 11/02/23

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest